287714-35-6

Basic information

• Product Name: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE
• Synonyms: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE;Methyl 2-chloropyriMidine...;2-Chloropyrimidine-5-carboxylic acid methyl ester;2-Chloro-5-(methoxycarbonyl)pyrimidine, 2-Chloro-5-(methoxycarbonyl)-1,3-diazine;2-chloro-pyrimidine-5-carboxylic acid methyl este;EOS-60344
• CAS NO: 287714-35-6
• Molecular Formula: C₆H₅ClN₂O₂
• Molecular Weight: 172.5691
• Product Categories: Heterocycles;Heterocycle-Pyrimidine series
• Mol File: 287714-35-6.mol

Chemical Properties

• Melting Point: 76 °C
• Boiling Point: 304.3℃
• Flash Point: 138℃
• Appearance: White to off-white powder
• Density: 1.372
• Vapor Pressure: 0.000883mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.14±0.22(Predicted)
• CAS DataBase Reference: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(287714-35-6)
• EPA Substance Registry System: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(287714-35-6)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 22-26-36/37/39
• RIDADR: UN2811
• Hazardous Substances Data: 287714-35-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-chloropyrimidine-5-carboxylate is used as a key intermediate in the synthesis of ACSS2 inhibitors. These inhibitors exhibit anti-inflammatory and anti-depressant activity, making them valuable for the development of new therapeutic agents to treat various inflammatory and mood disorders.

InChI:InChI=1/C6H5ClN2O2/c1-11-5(10)4-2-8-6(7)9-3-4/h2-3H,1H3

Upstream product

• 67-56-1 methanol 
• 374068-01-6 2-bromopyrimidine-5-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 308348-93-8 2-amino-pyrimidine-5-carboxylic acid methyl ester 

Downstream Products

• 38373-46-5 methyl 2-methoxy-5-pyrimidinecarboxylate 
• 38275-41-1 methyl 2-(methylthio)pyrimidine-5-carboxylate 
• 1020658-00-7 2-(6-(4-{[2-(trifluoromethyl)phenyl]oxy})pyridin-3-yl)pyrimidine-5-carboxylic acid 
• 1035270-11-1 2-(4-cyclopropylpiperazin-1-yl)-N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]pyrimidine-5-carboxamide 
• 1035271-70-5 methyl 2-(4-methyl-1,4-diazepan-1-yl)pyrimidine-5-carboxylate 
• 930111-21-0 2-morpholino-5-carboxymethylpyrimidine 
• 1046816-75-4 2-chloro-5-hydroxymethyl-pyrimidine 
• 1246381-01-0 2-{3-chloro-4-[2-(2-chloro-pyridin-4-yl)-3,3,3-trifluoro-2-hydroxy-1-methyl-propyl]-phenoxy}-pyrimidine-5-carboxylic acid methyl ester 
• 1268383-98-7 methyl [2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl]{2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinyl}acetate 
• 1268385-55-2 2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinecarboxylic acid 
• 1268385-57-4 methyl {2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinyl}acetate 
• 1268385-58-5 methyl bromo{2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinyl}acetate 
• 1268385-56-3 α-diazo-1-{2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinyl}ethanone 
• 1268385-61-0 C₁₅H₁₂ClF₃N₂O₂ 

Relevant articles and documents

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a BCL-2 inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and a BCL-2 inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a BCL-2 inhibitor and a pharmaceutically acceptable carrier or excipient.

CONDENSED BICYCLIC HETEROCYCLIC DERIVATIVE

PROBLEM TO BE SOLVED: To provide a compound having excellent retinoic acid receptor related orphan receptor γt inhibition effect and useful as a therapeutic agent for psoriasis or the like. SOLUTION: There is provided a compound represented by the general

Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The com-pounds can be used in methods of treating proliferative dis-eases and disorders such as cancer

AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems ofthe industrialized world In formula I, A-B is an arylamide moiety